Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Press Releases
AAPS Selects Certara Vice President of Research and Development Professor Amin Rostami as a Fellow
February 26, 2014
Amin Rostami, Pharm.D., Ph.D., FCP, Certara's vice president of research and development (R&D), has been selected as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in recognition of his professional excellence and contributions to the fields of pharmacokinetics and pharmacology.
Certara Conducts Model-based Meta-analysis to Compare Efficacy, Tolerability of Two Pain Medications
February 24, 2014
Data published in Pain and Therapy compare tramadol with tapentadol, provides an indirect comparison of the efficacy and tolerability profiles of the two medications.
Medivir AB Chooses Certara’s D360 as its Global Drug Discovery Platform
January 27, 2014
Medivir AB, a Swedish pharmaceutical company that focuses on infectious diseases including hepatitis C, has selected D360 as its global drug discovery platform. Certara’s D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data.
Professor Geoff Tucker Named President-Elect, International Society for the Study of Xenobiotics
January 20, 2014
Professor Tucker assumes the role of ISSX present-elect in 2014, and will become president in January 2015. He previously served two terms as an ISSX councilor from 1988 to 1991 and from 2004 to 2011.
Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara
December 19, 2013
Dr. James Rothman, a recipient of the 2013 Nobel Prize in Physiology or Medicine, evaluated the Certara acquisition in his role in Arsenal Capital Partners’ Healthcare Group and will become a Certara board member.
Certara Has Partnered With LabLogic Systems to Facilitate Faster Drug Discovery Analyses
December 10, 2013
Integration of Debra LIMS with Phoenix WinNonlin allows Debra 6 customers to port ADME and protein-binding data directly from Debra to Phoenix without manual manipulation.
Certara Partners With Thomson Reuters to Expand Data Access Through Its D360 Platform
October 22, 2013
Partnership to provide access to Thomson Reuters Cortellis™ for Informatics life sciences content through Certara's D360™ platform
Boehringer Ingelheim Selects Certara’s D360 as its Global Drug Discovery Platform
October 17, 2013
Plans to install D360 as global data mining tool at three of its sites, located in Ridgefield, CT; Biberach, Germany; and Vienna, Austria. All of the sites are currently using different data sources, mining tools, and workflows for analyzing the information.
American Chemical Society Presents Certara Chief Scientific Officer With 2013 Herman Skolnik Award
September 25, 2013
Dr. Richard D. Cramer III was honored for his innovations in computer-aided drug discovery and design at the American Chemical Society's Fall National Meeting.
Certara Partners with Critical Path Institute to Develop Population-based Lung Model
September 10, 2013
Certara is partnering with the Critical Path Institute (“C-Path”) to develop a physiologically-based pharmacokinetic (PBPK) model of the human lung. Built to work in conjunction with Certara’s Simcyp™ Population-based Simulator, the model will be used to predict the disposition of drugs within the lungs and the potential impact of disease-progression on drug kinetics at different stages of tuberculosis (TB) infection.
Simcyp Releases Version 13 of its Widely Used Simulator
August 28, 2013
Version 13 of the Simcyp™ Simulator has now been released, which permits the quantitative prediction of drug-drug-interactions and pharmacokinetic-pharmacodynamic outcomes in virtual populations.
Certara Signs Research Agreement with The Hamner Institutes for Health Sciences
August 20, 2013
Certara partners with the Hamner Institute to explore population-based model approach to help researchers assess the likelihood that drug exposure will result in liver toxicity using pre-clinical data.
Certara Announces Acquisition of Great Lakes Drug Development, Inc
August 12, 2013
Certara expands consulting team by acquiring Great Lakes Drug Development, Inc.; further increases drug development analysis, modeling and simulation expertise.
Certara Enhances SYBYL-X Drug Design and Discovery Software Suite
August 06, 2013
Certara releases SYBYL-X 2.1; customer-requested enhancements include new job control system to support distributed computing, Python toolkit for 3D-QSAR.
Certara Launches Cardiac Safety Simulator to Help Assess New Drug Candidates’ Arrhythmia Risk
August 01, 2013
Certara announces the launch of its Cardiac Safety Simulator™ (CSS), based on an in-silico model of human ventricular heart cells. When the CSS is integrated with Certara’s Simcyp™ Population-based Simulator, it allows for the in-vitro to in-vivo extrapolation of the pharmacokinetic and pharmacodynamic data to predict the likelihood that a drug candidate will exhibit cardiac toxicity.
Pfizer Deploys Certara’s D360 for Scientific Data Access and Analysis
July 29, 2013
Certara™ announced that Pfizer selected Certara’s D360™ software solution for scientific data access and analysis after a thorough evaluation and comparison with several other systems.
Certara’s Simcyp Appoints Professor Yuichi Sugiyama to the Certara Scientific Advisory Board
June 05, 2013
Certara™ announced that Simcyp Limited, a Certara company and a global leader in predictive pharmacokinetics, has announced the appointment of Yuichi Sugiyama, Professor Emeritus of the Graduate School of Pharmaceutical Sciences at The University of Tokyo and Head of the Sugiyama Laboratory within the RIKEN Innovation Center to the Certara Scientific Advisory Board (SAB).
Certara and Veristat Expand Clinical Trial Service Offerings with New Partnership
May 14, 2013
Certara and Veristat announce new partnership; collaboration offers expanded clinical trial service offerings, more efficient approach to clinical trial planning for clients.
Time to Tumor Growth Helps Predict Survival Benefit of Bevacizumab for Patients
May 08, 2013
Certara's Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer. These results are now published online in the Journal of Clinical Oncology. This approach of combining modeling with longitudinal tumor-size data may contribute to improved drug design and analysis of more informative early-stage clinical studies (Phase Ib, II), enable researchers to select the most promising treatments, and reduce the high attrition rate in Phase III oncology studies.
Certara Launches Drug Development Consulting Services for Asia
April 01, 2013
Hidefumi Kasai joins Certara’s Pharsight Scientific Consulting Services team; leads new Pacific Rim division.